Yazdanpanah Y - Search Results

1

Metabolic syndrome and endocrine status in HIV-infected transwomen.

Pommier JD, Laouénan C, Michard F, Papot E, Urios P, Boutten A, Peytavin G, Ghander C, Lariven S, Castanedo G, Moho D, Landman R, Phung B, Perez E, Julia Z, Descamps D, Roland-Nicaise P, Le Gac S, Yazdanpanah Y, Guibourdenche J, Yeni P. Pommier JD, et al. Among authors: yazdanpanah y. AIDS. 2019 Apr 1;33(5):855-865. doi: 10.1097/QAD.0000000000002152. AIDS. 2019. PMID: 30664006

2

Late diagnosis and subsequent survival among HIV-infected truck drivers in the northwest of France: a retrospective study.

Gras G, Geffray L, Parienti JJ, Yazdanpanah Y, Etienne M, Schmit JL, Verdon R; G4 study group. Gras G, et al. Among authors: yazdanpanah y. AIDS. 2009 Jul 17;23(11):1440-2. doi: 10.1097/QAD.0b013e32832d40c4. AIDS. 2009. PMID: 19448527 Clinical Trial.

3

Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen.

Charpentier C, Roquebert B, Colin C, Taburet AM, Fagard C, Katlama C, Molina JM, Jacomet C, Brun-Vézinet F, Chêne G, Yazdanpanah Y, Descamps D; ANRS 139 TRIO Trial study group. Charpentier C, et al. Among authors: yazdanpanah y. AIDS. 2010 Nov 13;24(17):2651-6. doi: 10.1097/QAD.0b013e32833ed2a7. AIDS. 2010. PMID: 20802293 Clinical Trial.

4

Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients.

Barrail-Tran A, Yazdanpanah Y, Goldwirt L, Chêne G, Colin C, Piketty C, Bollens D, Katlama C, Descamps D, Molina JM, Fagard C, Taburet AM; ANRS 139 study group. Barrail-Tran A, et al. Among authors: yazdanpanah y. AIDS. 2010 Oct 23;24(16):2581-3. doi: 10.1097/qad.0b013e32833d89fa. AIDS. 2010. PMID: 20960678

5

Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent.

Yuan J, Guo S, Hall D, Cammett AM, Jayadev S, Distel M, Storfer S, Huang Z, Mootsikapun P, Ruxrungtham K, Podzamczer D, Haas DW; Nevirapine Toxicogenomics Study Team. Yuan J, et al. AIDS. 2011 Jun 19;25(10):1271-80. doi: 10.1097/QAD.0b013e32834779df. AIDS. 2011. PMID: 21505298 Free PMC article.

6

Factors associated with virological failure in HIV-1-infected patients receiving darunavir/ritonavir monotherapy.

Lambert-Niclot S, Flandre P, Valantin MA, Peytavin G, Duvivier C, Haim-Boukobza S, Algarte-Genin M, Yazdanpanah Y, Girard PM, Katlama C, Calvez V, Marcelin AG. Lambert-Niclot S, et al. Among authors: yazdanpanah y. J Infect Dis. 2011 Oct 15;204(8):1211-6. doi: 10.1093/infdis/jir518. J Infect Dis. 2011. PMID: 21917894 Clinical Trial.

7

Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults.

Sloan CE, Champenois K, Choisy P, Losina E, Walensky RP, Schackman BR, Ajana F, Melliez H, Paltiel AD, Freedberg KA, Yazdanpanah Y; Cost-Effectiveness of Preventing AIDS Complications (CEPAC) investigators. Sloan CE, et al. Among authors: yazdanpanah y. AIDS. 2012 Jan 2;26(1):45-56. doi: 10.1097/QAD.0b013e32834dce6e. AIDS. 2012. PMID: 22008655 Free PMC article.

8

Burden of HIV disease and comorbidities on the chances of maintaining employment in the era of sustained combined antiretoviral therapies use.

Dray-Spira R, Legeai C, Le Den M, Boué F, Lascoux-Combe C, Simon A, May T, Goujard C, Meyer L; ANRS-COPANA Cohort Study Group. Dray-Spira R, et al. AIDS. 2012 Jan 14;26(2):207-15. doi: 10.1097/QAD.0b013e32834dcf61. AIDS. 2012. PMID: 22008658 Free PMC article.

9

Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial.

Fagard C, Colin C, Charpentier C, Rami A, Jacomet C, Yeni P, Vittecoq D, Katlama C, Molina JM, Descamps D, Chêne G, Yazdanpanah Y; ANRS 139 TRIO Trial Group. Fagard C, et al. Among authors: yazdanpanah y. J Acquir Immune Defic Syndr. 2012 Apr 15;59(5):489-93. doi: 10.1097/QAI.0b013e31824bb720. J Acquir Immune Defic Syndr. 2012. PMID: 22293546

10

Prevalence of subtype-related polymorphisms associated with in vitro resistance to attachment inhibitor BMS-626529 in HIV-1 'non-B'-infected patients.

Charpentier C, Larrouy L, Visseaux B, Landman R, Levittas M, Storto A, Damond F, Yazdanpanah Y, Yeni P, Brun-Vézinet F, Descamps D. Charpentier C, et al. Among authors: yazdanpanah y. J Antimicrob Chemother. 2012 Jun;67(6):1459-61. doi: 10.1093/jac/dks067. Epub 2012 Mar 1. J Antimicrob Chemother. 2012. PMID: 22382470

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

720 results

Search Page